A Covid vaccine booster aimed at tackling multiple variants shows promise in inducing a comprehensive immune response, early data in Britain suggests. The findings are published by US-based biotechnology company Gritstone bio, Inc. in collaboration with the University of Manchester and Manchester University NHS Foundation Trust. Data suggests it induced new T-cell responses and demonstrated the potential for variant-proof immunity. According to the researchers it also induced a boost to pre-existing T-cell responses. It is taking place within the National Institute of Health Research Manchester Clinical Research Facility (NIHR Manchester CRF) at Manchester Royal Infirmary, part of Manchester University NHS Foundation Trust (MFT).

Source: Irish Examiner January 05, 2022 00:25 UTC